EPITOME: Advancing Precision Oncology Diagnostics

Revolutionizing Precision Oncology

The concept of EpitomeTM is to seamlessly integrate histopathological analysis of tissue with reflex immunohistochemistry analysis (with as many immunostains as required), PDL1 (22C3) testing and reflex molecular testing (NGS + MSI + TMB) resulting in optimal cancer care and patient management.
Epitome will provide an end to end solution from tissue diagnosis to molecular testing, which provides necessary insights into precision oncogenomics, including targeted therapy and Immunotherapy.
Epitome is an innovative assay to decipher complex genomic data and offer treatment decisions on difficult-to-treat cases.

Epitome strives to make available for the patientcomprehensive histologic diagnosis, and actionable molecular biomarker testing in a reasonably fast timeline (10-14 days) to expedite and formulate treatment options.
Since complete testing would be done under one roof, it would save time in transfer of tissue between histopathology lab and molecular lab, thereby obviating the chance of case rejection on account of insufficient tumor content.
Our panel of experts will review every case and provide personalized diagnostic and therapeutic evaluation for each patient.
Our comprehensive molecular profiling approach precisely analyses DNA (SNVs, Indels, CNVs), RNA (fusions) and protein biomarkers (PDL1), thus providing a high quality molecular blueprint for evidence-based selection of the most appropriate cancer therapy.
The assay entails carefully selecting and utilizing tissue samples to maximize the efficiencyof molecular investigation, whileminimizing failure rates. In certain situations where genomic DNA is not amplifiable, liquid biopsy would be offered as an alternative option.